ArticlePediatric research2026
Stool biomarkers discriminate confirmed necrotizing enterocolitis in preterm infants.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotizing enterocolitis (NEC) is a major cause of morbidity and mortality in preterm infants. Early diagnosis remains challenging because clinical signs are nonspecific. We evaluated whether stool biomarkers could discriminate preterm infants with NEC from those without NEC.
methodsWe performed an ancillary analysis within the multicenter ClosNEC cohort of infants born before 32 weeks' gestation. Stool samples were collected at diagnosis in infants with confirmed NEC (Bell stage II or higher) and at comparable postnatal ages in preterm infants without NEC. Fecal calprotectin (fCal), human β-defensin-2, α1-antitrypsin (α1-AT), secretory immunoglobulin A (sIgA), cingulin (CGN), and eosinophil-derived neurotoxin were quantified using enzyme‑linked immunosorbent assay (ELISA) kits. Discriminatory performance was assessed using receiver operating characteristic analysis and logistic regression.
resultsThe analysis included 130 preterm infants: 42 with confirmed NEC and 88 without NEC. Biomarker concentrations differed between groups for all markers except CGN. sIgA showed the best individual discrimination (AUC = 0.82), followed by fCal (AUC = 0.74) and α1-AT (AUC = 0.73). The four-biomarker model yielded an AUC = 0.83, whereas the six-biomarker complete-case model yielded an AUC = 0.86.
conclusionStool biomarkers discriminated infants with NEC from those without NEC. Our findings support prospective validation in infants evaluated for suspected NEC, including clinically relevant comparator groups. IMPACT: Stool biomarkers distinguished infants with confirmed NEC from infants without NEC in a multicenter cohort. Secretory IgA showed the strongest individual discrimination, with an AUC of 0.82. A six-biomarker complete-case model yielded an AUC of 0.86 in 108 infants. These biomarkers are potential candidates for further evaluation as noninvasive tools for NEC assessment. Validation is needed in infants with suspected NEC and competing neonatal diagnoses.
Identifiers
42919831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.